Please login to the form below

Not currently logged in
Email:
Password:

haemophilia B

This page shows the latest haemophilia B news and features for those working in and with pharma, biotech and healthcare.

Spark sputters on haemophilia A gene therapy safety scare

Spark sputters on haemophilia A gene therapy safety scare

Spark sputters on haemophilia A gene therapy safety scare. Investors compare data unfavourably with BioMarin rival. ... While there is more to do, I am excited about what Spark has achieved in both haemophilia A and haemophilia B and I have no doubt now

Latest news

More from news
Approximately 3 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... Portfolio/pipeline in haemophilia and other

  • Deal Watch August 2016 Deal Watch August 2016

    premiums. One commentator suggested BioMarin could be a Plan B for Sanofi. ... This will help with the collaboration with Spark Therapeutics that is developing a treatment for haemophilia B that incorporates a bio-engineered rAAV vector and the academic

  • A rare opportunity A rare opportunity

    Sobi, handing Sobi commercialisation control over the haemophilia A treatment just four months after it received EU approval. ... Last month Alprolix was approved by the European Commission, becoming the first licenced long-acting treatment for

  • Deal Watch February 2016 Deal Watch February 2016

    Indeed Baxalta already has ongoing gene therapy programmes for the treatment of haemophilia A and B.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Exercise of opt-out/ termination. 945. Macrogenics / J&J. MGD011, bispecific DART antibody for B-cell haematological malignancies (preclinical). ... Licence - amended agreement. † 300. Spark Therapeutics / Pfizer. Multiple haemophilia B gene therapy

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
HAVAS LYNX

Welcome to HAVAS LYNX, a leading global healthcare communications group....

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics